公开(公告)号：US20240002503A1

公开(公告)日：2024-01-04

申请号：US18249966

申请日：2021-10-20

申请人： IMMUNE-ONC THERAPEUTICS, INC.

发明人： Maria Jose COSTA ,  Ryan STAFFORD ,  Krista MCCUTCHEON ,  Jing-Tyan MA ,  Kyu Hee HONG ,  Hongyu TIAN ,  An SONG ,  X. Charlene LIAO

IPC分类号： C07K16/28 ,  C12N15/63 ,  G01N33/574 ,  A61P35/00 ,  A61K39/00 ,  C12N5/078

CPC分类号： C07K16/2803 ,  C12N15/63 ,  G01N33/574 ,  A61P35/00 ,  A61K39/4631 ,  A61K39/461 ,  C12N5/0634 ,  C07K2317/24 ,  C07K2317/31

摘要： The present disclosure provides anti-LILRB2 antibodies or antigen-binding fragments thereof, anti-LILRB2 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

公开(公告)号：US20230340114A1

公开(公告)日：2023-10-26

申请号：US17905943

申请日：2021-03-12

申请人： IMMUNE-ONC THERAPEUTICS, INC.

发明人： An SONG ,  Tao HUANG ,  Ryan STAFFORD ,  Maria Jose COSTA ,  Kyu Hee HONG ,  Caroline BONNANS ,  Jianhui ZHOU ,  Li ZHOU ,  Ji LI ,  J. Paul WOODARD ,  X. Charlene LIAO

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  C12N5/0783 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  A61P35/02 ,  A61K38/17

CPC分类号： C07K16/2803 ,  C07K16/2809 ,  A61K45/06 ,  A61K39/3955 ,  C12N5/0636 ,  A61K39/4611 ,  A61K39/4622 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/7051 ,  A61K39/4631 ,  A61P35/02 ,  A61K38/1774 ,  A61K38/177 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/732 ,  C07K2317/73 ,  C07K2319/33 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/02 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/29 ,  C07K2317/92

摘要： The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, anti-LILRB4 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

公开(公告)号：US20230068663A1

公开(公告)日：2023-03-02

申请号：US17759800

申请日：2021-01-28

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

发明人： Zhiqiang AN ,  Ningyan ZHANG ,  Zhiqiang KU ,  Chengcheng ZHANG ,  Xiaoye XU ,  Heyu CHEN ,  JingJing XIE ,  Maria Jose COSTA ,  An SONG ,  X. Charlene LIAO

IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61P35/02 ,  A61K39/395 ,  G01N33/574

摘要： Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US20210371518A1

公开(公告)日：2021-12-02

申请号：US17275838

申请日：2019-09-12

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

发明人： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Xun GUI ,  Mi DENG ,  Tao HUANG ,  Qiang LIU ,  X. Charlene LIAO

IPC分类号： C07K16/28 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  G01N33/574 ,  A61K47/69

摘要： The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.